S
Stelios Papadopoulos
Researcher at Exelixis
Publications - 6
Citations - 158
Stelios Papadopoulos is an academic researcher from Exelixis. The author has contributed to research in topics: Valuation (finance) & Initial public offering. The author has an hindex of 3, co-authored 6 publications receiving 146 citations.
Papers
More filters
Journal ArticleDOI
Business models in biotech
TL;DR: Companies with technology platforms that address only a tiny part of the drug discovery process risk becoming optional or redundant accessories.
Journal ArticleDOI
Evolving paradigms in biotech IPO valuations.
TL;DR: Going public with a valuation higher than $300 million may now be necessary to attract interest from institutional investors.
Journal ArticleDOI
Biotechnology's consolidation conundrum.
TL;DR: If consolidation is a means for corporate survival, why do so many biotechnology companies consider it a dirty word?
Journal ArticleDOI
Quantifying the dream: Valuation approaches in biotechnology
TL;DR: Bioentrepreneurs should have a keen grasp of how Wall Street determines value in order to prepare their company for public markets.